Aging Vaccines

It is somewhat ironic that some of the very countries, who earlier showed reluctance to give the Oxford/AstraZeneca Covid-19 vaccine to older people, are now restricting its use to the mature (https://www.theguardian.com/society/2021/apr/08/spain-belgium-and-italy-restrict-astrazeneca-covid-vaccine-to-older-people ). When the Oxford/AstraZeneca Covid-19 vaccine was first approved, a number of European Union (EU) countries precluded its use in older (actually the most at risk) patients. The claim was that there was insufficient data on the use of the vaccine in older people. Now, because of the claimed association with the vaccine's administration and a very rare blood clotting condition, they are doing the reverse. Belgium is only giving this vaccine to the over 55's and Italy, as well as Spain, to those who are 60+. Even in the UK, younger people will be offered an alternative vaccine, 'if one is available in their area'. Bizzarely, we probably know less about side-effects in any alternatives (they have not been used to anything like the same extent). This is, in spite of assurances from all regulatory agencies, that the benefits of getting the Oxford/AstraZeneca vaccine, greatly outweigh any risks. Young people have a much greater danger of dying in a car crash, than developing the blood clot condition. I suspect that this dithering will only fuel vaccine hesitancy.